Traders bought shares of Pfizer Inc. (NYSE:PFE) on weakness during trading hours on Wednesday. $294.14 million flowed into the stock on the tick-up and $211.91 million flowed out of the stock on the tick-down, for a money net flow of $82.23 million into the stock. Of all stocks tracked, Pfizer had the 3rd highest net in-flow for the day. Pfizer traded down ($0.80) for the day and closed at $35.29

A number of equities analysts recently issued reports on the company. Barclays PLC restated an “equal weight” rating and issued a $34.00 target price on shares of Pfizer in a research note on Tuesday. Sanford C. Bernstein set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Tuesday. Vetr lowered Pfizer from a “buy” rating to a “hold” rating and set a $37.97 target price for the company. in a research note on Thursday, July 14th. Jefferies Group restated a “buy” rating on shares of Pfizer in a research note on Monday. Finally, JPMorgan Chase & Co. set a $40.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Monday, July 25th. Ten analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $38.23.

The stock has a market cap of $214.03 billion and a PE ratio of 28.93. The company’s 50 day moving average is $35.78 and its 200-day moving average is $32.72.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.02. The firm had revenue of $13.10 billion for the quarter, compared to analysts’ expectations of $13.01 billion. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.56 earnings per share. On average, equities research analysts forecast that Pfizer Inc. will post $2.45 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 1st. Investors of record on Friday, August 5th will be issued a dividend of $0.30 per share. The ex-dividend date is Wednesday, August 3rd. This represents a $1.20 annualized dividend and a yield of 3.40%.

In other Pfizer news, EVP Frank A. Damelio sold 100,000 shares of the company’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $34.49, for a total transaction of $3,449,000.00. Following the transaction, the executive vice president now directly owns 472,994 shares in the company, valued at $16,313,563.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sally Susman sold 76,116 shares of the company’s stock in a transaction dated Thursday, May 5th. The stock was sold at an average price of $33.75, for a total transaction of $2,568,915.00. Following the transaction, the executive vice president now owns 195,951 shares in the company, valued at $6,613,346.25. The disclosure for this sale can be found here.

Other hedge funds and institutional investors recently modified their holdings of the company. MetLife Securities Inc raised its position in shares of Pfizer by 71.3% in the fourth quarter. MetLife Securities Inc now owns 221,106 shares of the biopharmaceutical company’s stock valued at $7,137,000 after buying an additional 92,009 shares during the last quarter. Savant Capital LLC raised its position in shares of Pfizer by 10.5% in the fourth quarter. Savant Capital LLC now owns 64,211 shares of the biopharmaceutical company’s stock valued at $2,073,000 after buying an additional 6,082 shares during the last quarter. First Trust Advisors LP raised its position in shares of Pfizer by 30.3% in the fourth quarter. First Trust Advisors LP now owns 2,797,198 shares of the biopharmaceutical company’s stock valued at $90,294,000 after buying an additional 650,410 shares during the last quarter. Busey Trust CO raised its position in shares of Pfizer by 1.5% in the fourth quarter. Busey Trust CO now owns 496,458 shares of the biopharmaceutical company’s stock valued at $16,025,000 after buying an additional 7,124 shares during the last quarter. Finally, Smithfield Trust Co. raised its position in shares of Pfizer by 2.4% in the fourth quarter. Smithfield Trust Co. now owns 75,268 shares of the biopharmaceutical company’s stock valued at $2,429,000 after buying an additional 1,764 shares during the last quarter.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.